Cáncer

EGFR and K-Ras in non-small cell lung cancer- molecular pathway and targeted therapies

Impact of CYP3A5 and ABCB1 gene polymorphisms in cancer patients

Multifactorial PGx analysis in CR cancer patients receiving 5-fluorouracil

Breast cancer pharmacogenomics - where we are going

CYP2D6 genotyping and antidepressants in breast cancer patients

Pediatric ALL-where are we going and how do we get there

Meta-analysis on PGx of platinum-based chemotherapy in NSCLC patients

Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with CML

Can pharmacogenomics guide efective anticancer therapy in pancreatic ductal adenocarcinoma

Association Imatinib transporters and metabolizing enzymes genotype response in CML patients

The clinically relevant pharmacogenomic changes in acute myelogenous leukemia

Pharmacogenetic biomarkers for the predictoin of response to antiangiogenic treatment

Frequencies of 23 variant alleles related with metabolism of antineoplastic drugs

SLC22A1-ABCB1 haplotype predict Imatinib pharmacokinetics Asian patients with CML

Polymorphisms of UDP-GT 1A genes associated with adverse events in cancer patients

Cisplatin-induced ototoxicity and the role of pharmacogenetic testing

Nuclear factor-kappa B as a resistance factor to platinum-based antineoplasic drugs

Herb-drug interactions in oncology -focus on mechanisms of induction

Silent polymorphisms speak-how they affect PGx and treatment of cancer

Functional genetic polymorphisms in aromatase gene CYP19 vary response breast cancer patients to